Stephen Keim, MD
Clinical Cardiac Electrophysiology · Salisbury, MDNPI 1821080029
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (39.0%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. Medtronic accounts for 86.0% of it on its own, with 22 other manufacturers making up the rest. Reporting peaked in 2019 at $7,730 and has fallen 98.6% since, to $108 in 2025.
Across 158 payments — averaging $110.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$15K
- Abbott$643
- Boston Scientific$301
- Biosense Webster, Inc.$250
- Medical Device Business Services, Inc.$246
- Atricure, Inc.$207
- plus $798 from 17 others
Across 79 payments — averaging $1135.46 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$63K
- Boston Scientific$23K
- Abbott$4K
What the payments were for
- Consulting fees$6,10035%
- Travel & lodging$6,81239%
- Food & beverage$4,56826%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 79 | $15,035 |
| Abbott | 13 | $643 |
| Boston Scientific | 11 | $301 |
| Biosense Webster, Inc. | 7 | $250 |
| Medical Device Business Services, Inc. | 2 | $246 |
| Atricure, Inc. | 4 | $207 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 6 | $171 |
| Merit Medical Systems Inc | 1 | $114 |
| Johnson & Johnson | 7 | $105 |
| Irhythm Technologies, Inc. | 6 | $85 |
| Novartis | 4 | $66 |
| Amarin Pharma, Inc. | 3 | $50 |
| Amgen | 3 | $42 |
| Pfizer | 2 | $32 |
| AstraZeneca | 2 | $24 |
| Cordis US CORP. | 1 | $20 |
| Lundbeck LLC | 1 | $17 |
| Boehringer Ingelheim | 1 | $15 |
| E.r. Squibb & Sons, L.L.C. | 1 | $15 |
| Cardiva Medical, Inc. | 1 | $14 |
| Cook Medical LLC | 1 | $13 |
| Amryt Pharma Holdings Ltd | 1 | $11 |
| Cvrx, Inc. | 1 | $4 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$17,480 in reported general payments places this provider in the 55th percentile of 63 clinical cardiac electrophysiology providers in Maryland.
See all clinical cardiac electrophysiology providers in Maryland →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 129 | $112,987 |
| EntrestoSacubitril/Valsartan | 37 | $43,517 |
| XareltoRivaroxaban | 21 | $26,821 |
| JardianceEmpagliflozin | 20 | $14,268 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 13 | $3,060 |
| Nadolol | 22 | $1,328 |
| Labetalol Hcl | 41 | $1,075 |
| Amiodarone Hcl | 71 | $927 |
| Metoprolol Succinate | 64 | $800 |
| Flecainide Acetate | 21 | $644 |
| Bisoprolol Fumarate | 12 | $473 |
| Digoxin | 18 | $424 |
| SotalolSotalol Hcl | 21 | $339 |
| Atorvastatin Calcium | 33 | $312 |
| Valsartan | 21 | $298 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $32 | $112,987129 claims |
| NovartisEntresto | $66 | $43,51737 claims |
| Johnson & JohnsonXarelto | $105 | $26,82121 claims |
| Boehringer IngelheimJardiance | $15 | $14,26820 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 63 clinical cardiac electrophysiology providers in Maryland.
Other clinical cardiac electrophysiology in Salisbury
- Akhil ParasharSalisbury$58K
- Scott KaufmanSalisbury$11K
- Emmanuel NsahSalisbury$10K
- Sean BeinartRockville$315K
- Charles LoveBaltimore$238K
- Hugh CalkinsBaltimore$202K
- Paresh ShahBaltimore$97K
- Helen BaroldRockville$83K
- Jonathan ChrispinBaltimore$77K
- Sung LeeTakoma Park$68K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.